Enantioselective LC/ESI-MS/MS analysis and pharmacokinetic and tissue distribution study of (2RS)-1-(7-methoxy-1H-indol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)-propan-2-ol in rats.
A sensitive and stereospecific liquid chromatography-tandem mass spectrometry method for the quantitative determination of TWo8 enantiomers ((2RS)-1-(7-methoxy-1H-indol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)-propan-2-ol) was developed and validated in rat serum and some tissues. Racemic TWo8 is a new chemical entity, and it has been shown to possess pharmacological activity in vivo. The assay involved the diastereomeric derivatization of racemic TWo8 with 2,3,4,6-tetra-O-acetyl-beta-glucopyranosyl isothiocyanate. The TWo8 diastereoisomers quantification was performed on a triple quadrupole mass spectrometer employing an electrospray ionization technique. The precursor to the product ion transition for TWo8 derivatives and for the internal standard (carbamazepine) was m/z 776.4 → 387.2 and 237.4 → 194.4, respectively. The assay was validated with a linear range of 10-2000 ng/ml of racemic TWo8. The inter-day precisions for (-)-(S)-TWo8 and (+)-(R)-TWo8 were 2.1% to 14.9% and 1.3% to 14.8%, respectively. The inter-day accuracy for (-)-(S)-TWo8 and (+)-(R)-TWo8 was within 86% to 114% and 91% to 114%, respectively. A pilot pharmacokinetic study of this new β-adrenolytic compound has shown that (-)-(S)-TWo8 is eliminated faster than its antipode. The terminal half-lives of (-)-(S)-TWo8 and (+)-(R)-TWo8 were 3.2 and 3.9 h, respectively. The compound distribution into different organs, evaluated in tissue homogenate samples following TWo8 intravenous administration, showed an enantioselective penetration of TWo8 enantiomers in the liver (p < 0.03), in the kidney (p < 0.001), and in the lungs (p < 0.05). The developed method using liquid chromatography-tandem mass spectrometry method with electrospray ionization could be employed for quantitative determination of compounds with similar structure.
Department of Pharmacokinetics and Physical Pharmacy, Jagiellonian University Medical College, Kraków, Poland. mwalczak.farm@poczta.fm
Maria
M
Walczak
Joanna
J
Szymura-Oleksia
Grazyna
G
Groszek
D000433:1-Propanol / Q000032:analysis* / Q000737:chemistry / Q000302:isolation & purification / Q000493:pharmacokinetics*; D018674:Adrenergic Antagonists / Q000032:analysis* / Q000737:chemistry / Q000302:isolation & purification / Q000493:pharmacokinetics*; D000818:Animals; D002138:Calibration; D002851:Chromatography, High Pressure Liquid; D007211:Indoles / Q000032:analysis* / Q000737:chemistry / Q000302:isolation & purification / Q000493:pharmacokinetics*; D017879:Isothiocyanates / Q000737:chemistry; D057230:Limit of Detection; D008297:Male; D011412:Propanolamines / Q000032:analysis* / Q000737:chemistry / Q000302:isolation & purification / Q000493:pharmacokinetics*; D051381:Rats; D017208:Rats, Wistar; D021241:Spectrometry, Mass, Electrospray Ionization; D013237:Stereoisomerism; D013379:Substrate Specificity; D053719:Tandem Mass Spectrometry; D014018:Tissue Distribution
C579251:1-(7-methoxy-1H-indol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)propan-2-ol; D018674:Adrenergic Antagonists; D007211:Indoles; D017879:Isothiocyanates; D011412:Propanolamines; C041943:2,3,4,6-tetra-O-acetylglucopyranosylisothiocyanate; D000433:1-Propanol